<DOC>
	<DOC>NCT01498952</DOC>
	<brief_summary>A Phase 1b/2, open-label, randomized study to evaluate MEDI-573 in combination with standard of care in adult subjects with unresectable or metastatic HCC.</brief_summary>
	<brief_title>MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age ≥ 18 years or minimum age of consent per local regulations at the time of screening Unresectable or metastatic hepatocellular carcinoma ECOG Performance Status ≤ 2 Life expectancy of ≥ 3 months; ChildPugh Score for Cirrhosis Mortality &gt; 7 points Prior or current system anticancer therapy for HCC, including cytotoxic, biologic, targeted or experimental therapy Prior local treatment for HCC less than 4 weeks prior to initiating study treatment Active second malignancy Major surgery, open biopsy or significant traumatic injury within 4 weeks prior to initiating study treatment Thrombotic or embolic events within 6 months prior to initiating study treatment Ongoing pancreatitis Uncontrolled or refractory ascites Evidence of ongoing spinal cord compression, known carcinomatous meningitis, or known leptomeningeal carcinomatosis Hepatic encephalopathy &gt; Grade 1 Active brain metastases with exceptions Poorly controlled diabetes mellitus Active coronary artery disease Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>HCC, liver cancer, hepatocellular carcinoma, MEDI-573, anti-IGF</keyword>
</DOC>